Cancer Therapy News and Research

RSS

Modifi Bio comes up with a new technology to combat cancer cells with DNA modification

Modifi Biosciences announced today that the journal Science has published a critical study validating the company's novel oncology platform based on new classes of molecules that exploit tumor-associated DNA repair defects through direct cancer cell DNA modification.

29 Jul 2022

Repurposing an antipsychotic drug to treat various types of cancer

To treat some of the psychosis issues associated with Parkinson's disease, physicians often prescribe pimavanserin, an antipsychotic drug that acts within the brain to prevent hallucinations and delusions.

28 Jul 2022

Creating a Microrobot to One Day Tackle Cancer

In this interview, we speak to Birgül Akolpoglu about her latest research into microrobotics and how these biohybrid microrobots could one day be used to tackle cancer.

27 Jul 2022

Two UTHSC research teams receive CORNET Awards for novel projects

Two research teams at the University of Tennessee Health Science Center (UTHSC) have been awarded the 2022 UTHSC Collaborative Research Network (CORNET)-Functional Genomics Award. Each team will receive $50,000 to support their novel projects.

22 Jul 2022

Study shows how a critical Lassa virus protein drives infection

Lassa fever is a viral illness that is far too common in West Africa. Although it can have a mortality rate of 15 percent in severe cases, up to 90% in pregnant women, and causes deafness in a quarter of survivors, there is no vaccine or antiviral to protect against Lassa virus.

19 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Study: Certain genetic features predispose lung cancer patients to develop immunotherapy side effects

Lung cancer is the deadliest form of cancer, accounting for an estimated 1.8 million deaths worldwide.

14 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

Understanding the impact of bladder cancer on daily life before and after diagnosis

In this interview, Dr. Ignacio Durán and Alex Filicevas, discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. They focus on the quality of life for patients and delve into the impact bladder cancer has on daily life, both before and after diagnosis and treatment, from the holistic perspective of both patients and HCPs.

From Janssen Pharmaceuticals 4 Jul 2022

Treatment resistance for deadly form of kidney cancer linked to low mitochondrial content in the cell

Researchers at Karolinska Institutet in Sweden have linked resistance to treatment for a deadly form of kidney cancer to low mitochondrial content in the cell.

27 Jun 2022

Molecular tumor profiling in pediatric cancer patients significantly impacts clinical care

Results of a study of molecular tumor profiling in young patients revealed a high rate of genetic alterations with potential for impacting clinical care, including clarifying diagnoses and treatment with matched, precision cancer drugs.

23 Jun 2022

Multifunctional nanoparticle system may be a promising therapeutic way for breast cancer therapy

In this new article publication from Acta Pharmaceutica Sinica B, authors Yun Yang, Danrong Hu, Yi Lu, Bingyang Chu, Xinlong He, Yu Chen, Yao Xiao, Chengli Yang, Kai Zhou, Liping Yuan and Zhiyong Qian from Sichuan University, Chengdu discuss tumor-targeted/reduction-triggered composite multifunctional nanoparticles for breast cancer chemo-photothermal combinational therapy.

18 Jun 2022

Study points to a new direction for the development of NAMPT-targeted cancer therapies

In this new article publication from Acta Pharmaceutica Sinica B, authors Ying Wu, Congying Pu, Yixian Fu, Guoqiang Dong, Min Huang and Chunquan Sheng from Second Military Medical University, Shanghai, China and University of Chinese Academy of Sciences, Shanghai, China discuss how NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion.

18 Jun 2022

Researchers investigate COVID fog and chemokine C–C motif ligand 11

Researchers assessed the characteristics of the brain fog reported by some COVID-19 patients.

17 Jun 2022

Researchers identify a signature of three genes linked to positive response to blood cancer therapy

Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.

16 Jun 2022

Even mild respiratory COVID can affect the brain

In a recent study published in the journal Cell, researchers explored neurological symptoms and subsequent cognitive impairment experienced by survivors of mild respiratory coronavirus disease 2019 (COVID-19).

14 Jun 2022

Androgens contribute to sex bias in bladder cancer

Male sex hormones interfere with the body's ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study co-led by a Cedars-Sinai Cancer investigator.

10 Jun 2022

Researchers reveal important factor behind cancer therapy resistance and a way to counter it

Why doesn't every cancer patient respond to immunotherapy? That's the question that researcher Daniel Peeper is looking to answer.

9 Jun 2022

New trial examines the effectiveness of combination immunotherapy for platinum-resistant ovarian cancer

A new clinical trial studying the effectiveness of a combination of immunotherapy treatments could be more effective for patients with ovarian cancer who are resistant to traditional interventions.

6 Jun 2022

$New combination of drugs increases survival time for some patients with refractory lung cancer$

New combination of drugs increases survival time for some patients with refractory lung cancer

A combination of the drugs ramucirumab and pembrolizumab reduced risk of death by 31% compared with the standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.

3 Jun 2022